Opioid detox for Boynton Beach — fentanyl-era protocols, buprenorphine done right.

RECO Island sits 7 miles south of Boynton Beach on Federal Highway — a 12-minute drive from Renaissance Commons or Ocean Ridge. Opioid detox is COWS-guided, buprenorphine-forward, and staffed for the fentanyl era, with 24/7 nursing and physician management. Every client transitions directly in-house from detox into residential rehab — no waitlists, no third-party handoffs, and naloxone education at discharge as standard of care.

For someone in Renaissance Commons or Ocean Ridge, the drive south down Federal Highway to RECO Island’s Delray Beach campus takes about 12 minutes — shorter than the trip to a good supermarket in Boynton. That proximity is a clinical asset. An opioid detox admission from Boynton Beach doesn’t require air travel, out-of-state placement, or the logistical friction that keeps people from starting treatment when they finally decide to.

RECO Island runs a small-census, physician-led medical detox followed by direct in-house transition to residential rehab. For opioid detox, that continuity matters more than almost any other feature of the program — the window between finishing acute withdrawal and re-engaging with the world is the window in which relapse and overdose most often happen.

Opioid withdrawal in the fentanyl era

Fentanyl and its analogs have materially changed how opioid withdrawal is managed. Fentanyl is roughly a hundred times more potent than morphine and deposits in fat tissue, producing a pharmacokinetic profile that is neither predictable across patients nor consistent within a single patient over time. Withdrawal in fentanyl-exposed clients often emerges faster than the pre-fentanyl playbook suggests, escalates more sharply, and is prone to atypical presentations — including protracted autonomic symptoms and pronounced dysphoria that don’t map cleanly onto a COWS score alone.

Buprenorphine induction, once reliably initiated at 12 to 24 hours of moderate withdrawal from heroin or short-acting prescription opioids, now frequently requires longer waiting periods, low-dose induction, or full micro-induction protocols to avoid precipitated withdrawal. Street adulterants — xylazine most notably, but also benzodiazepine analogs and other unpredictable cuts — further complicate the picture and can require concurrent management. Detox protocols that were state-of-the-art in 2015 are not state-of-the-art today.

RECO Island’s opioid detox protocol reflects current addiction medicine practice. Physician management, 24/7 nursing, and access to micro-induction protocols where indicated are the baseline, not an upgrade. Clients are re-assessed continuously through the first 72 hours rather than only at admission and discharge.

COWS-guided buprenorphine induction

The Clinical Opiate Withdrawal Scale (COWS) scores eleven symptom domains — resting pulse, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, GI upset, tremor, yawning, anxiety or irritability, and gooseflesh — to produce a numeric picture of withdrawal severity. Standard buprenorphine induction begins when COWS crosses the moderate threshold, typically 11 or above, with a starting dose of 2 to 4 mg sublingual. Additional doses are titrated over the first 24 hours to a clinically effective daily dose, usually 8 to 16 mg.

For fentanyl-exposed patients, standard induction can precipitate severe withdrawal at COWS scores that would previously have been considered safe. Low-dose induction (starting at 0.5 mg and stepping up over several days while the client remains on their prior opioid) and true micro-induction protocols are both options RECO Island uses when clinically indicated. The decision is made by the attending physician based on last use, quantity, product source, and clinical presentation — not by a rigid one-protocol-fits-all algorithm.

Comfort medications supplement induction rather than replace it. Clonidine addresses autonomic symptoms — tachycardia, hypertension, sweating, restlessness. Loperamide targets GI symptoms and ondansetron manages nausea. Non-benzodiazepine muscle relaxants, hydroxyzine, and short-course trazodone can address myalgias and insomnia. The goal is not sedation; it is a tolerable withdrawal that lets the client engage with the psychosocial work that begins during detox using MI and early CBT and continues in residential care.

Buprenorphine, methadone, or naltrexone — the MAT decision

Post-detox medication for opioid use disorder has three options supported by strong evidence: buprenorphine, methadone, and extended-release naltrexone. Each has a distinct pharmacology, a distinct treatment setting, and a distinct patient profile it fits best. The decision is made during the detox stay, with the client, not deferred to a hurried discharge conversation.

Buprenorphine (Suboxone, Subutex, Sublocade injection) is a partial mu-opioid agonist with a ceiling effect on respiratory depression, giving it a substantially lower overdose risk than full agonists. It is office-based, meaning it can be continued through a primary care or addiction medicine prescriber after discharge without daily clinic attendance. Methadone is a full mu-opioid agonist dispensed through federally licensed opioid treatment programs; it carries the strongest evidence for patients with very high tolerance or prior buprenorphine failure, at the cost of daily on-site dosing. Extended-release naltrexone (Vivitrol) is a monthly intramuscular opioid antagonist — it requires a documented 7 to 10 day opioid-free period before initiation, which is one of the reasons medically managed detox is a prerequisite for this pathway.

Recommendations are made jointly by the attending physician, the client, and where appropriate, family. Prior response, current tolerance, employment considerations, and access to prescribers in the client’s home area all factor in. A Boynton Beach resident returning to a job that involves random drug screening has different practical considerations than a client without that constraint.

Naloxone education and the safety net

Every client completing opioid detox at RECO Island — and every family member who wants to attend — receives naloxone education and a naloxone prescription at discharge. This is not optional programming and it is not a marketing feature. Overdose mortality in the 30 days after opioid detox is elevated relative to any other window in the illness. Physiologic tolerance falls sharply during detox; if a return to use occurs, the dose that felt normal two weeks earlier can be fatal.

The evidence-based interventions that shrink that mortality window are well established: continuation of MAT (buprenorphine or naltrexone), naloxone in the home, family training on overdose recognition, and warm handoff to residential or PHP care rather than discharge to unstructured time. RECO Island’s direct in-house transition to residential rehab is designed around exactly this data — the immediate post-detox period should not be a gap.

Household contacts are trained to recognize the presentation of opioid overdose — pinpoint pupils, unresponsiveness, shallow or absent respirations, cyanosis — and to administer intranasal naloxone. This is standard medical practice, not a comment on the client’s likelihood of return to use.

What to expect on your first visit

Admission from Boynton Beach typically begins with a phone call to the admissions team, insurance verification, and a same-day or next-day intake. Arrival on-site includes a medical history, a physical exam, a COWS assessment, urine toxicology, and a psychiatric evaluation. Co-occurring depression, anxiety, PTSD, and bipolar disorder are screened using standardized instruments including PHQ-9, GAD-7, PCL-5, and MDQ — not because the paperwork requires it, but because untreated psychiatric comorbidity is a leading driver of return to opioid use.

The ASAM Criteria six-dimensional assessment determines level of care and informs the treatment plan. Clients meet the attending physician, the nursing team, and the case manager within the first few hours. A private room and initial medication orders — buprenorphine timing based on the COWS trajectory, comfort medications as needed — are in place before the first night.

Insurance and admissions from Boynton Beach

RECO Island is in-network with most major commercial insurers, including Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS plans. Verification of benefits is completed by the admissions team, typically within the same phone call, with a specific out-of-pocket estimate before admission. Cash-pay and single-case agreements are also available.

Because RECO Island runs a small census by design, admissions from Boynton Beach are usually same-day. There is no waitlist and no third-party marketing intermediary between the caller and the clinical team. The person answering the phone is the person coordinating the admission.

Serving residents of: Renaissance Commons, Ocean Ridge, Quantum Park, Hunters Run, Briny Breezes.